Abstract
Introduction. Patients with diabetes mellitus (DM) are reported to experience more severe erectile dysfunction (ED) symptoms and respond less to ED treatments compared with patients with ED of other etiologies. Aim. This study was undertaken to evaluate the safety and efficacy of udenafil for the treatment of ED in a larger number of patients with DM. Methods. A placebo-controlled, randomized, double-blind, double-dummy, parallel-group design multicenter study, fixed-dose trial was conducted. The trial involved seven study sites in Korea, with 174 ED patients with DM. The subjects, treated with placebo, 100mg, or 200mg of udenafil for 12 weeks, were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Question (GAQ) during the study period. Main Outcome Measures. The primary efficacy parameter was the change in the erectile function domain (EFD) score of IIEF from baseline. Secondary parameters were IIEF questions 3 (Q3) and Q4, SEP Q2 and Q3, rate of achieving normal erectile function (EFD≥26), and the response to GAQ. Results. Compared with the placebo, patients receiving both doses of udenafil showed statistically significant improvements in the IIEF-EFD score, respectively. However, statistically significant difference was not observed between the udenafil 100mg and the udenafil 200mg groups. Similar results were observed in the comparison of Q3 and Q4 of IIEF, SEP diary, and GAQ. The percentages of subjects experiencing at least one adverse event related to the study drugs were 3.6%, 15.8%, and 22.4% for the placebo, udenafil 100mg, and udenafil 200mg groups, respectively. However, these events were all mild in severity. Major adverse events were flushing, headache, nausea, and conjunctival hyperemia. Conclusion. Udenafil was significantly effective for the treatment of ED, demonstrating statistically significant improvement in erectile function in patients with DM. The incidence of adverse events was relatively low and well tolerated in patients with DM.
| Original language | English |
|---|---|
| Pages (from-to) | 2048-2061 |
| Number of pages | 14 |
| Journal | Journal of Sexual Medicine |
| Volume | 8 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2011 Jan 1 |
Fingerprint
Keywords
- Diabetes mellitus
- Erectile dysfunction
- Pharmacotherapy for erectile dysfunction in men with diabetes
- Udenafil
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynaecology
- Urology
Cite this
A therapeutic confirmatory study to assess the safety and efficacy of Zydena® (Udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. / Moon, Du Geon; Yang, Dae Yul; Lee, Choong Hyun; Ahn, Tai Young; Min, Kweon Sik; Park, Kwangsung; Park, Jong Kwan; Kim, Je-Jong.
In: Journal of Sexual Medicine, Vol. 8, No. 7, 01.01.2011, p. 2048-2061.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A therapeutic confirmatory study to assess the safety and efficacy of Zydena® (Udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus
AU - Moon, Du Geon
AU - Yang, Dae Yul
AU - Lee, Choong Hyun
AU - Ahn, Tai Young
AU - Min, Kweon Sik
AU - Park, Kwangsung
AU - Park, Jong Kwan
AU - Kim, Je-Jong
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Introduction. Patients with diabetes mellitus (DM) are reported to experience more severe erectile dysfunction (ED) symptoms and respond less to ED treatments compared with patients with ED of other etiologies. Aim. This study was undertaken to evaluate the safety and efficacy of udenafil for the treatment of ED in a larger number of patients with DM. Methods. A placebo-controlled, randomized, double-blind, double-dummy, parallel-group design multicenter study, fixed-dose trial was conducted. The trial involved seven study sites in Korea, with 174 ED patients with DM. The subjects, treated with placebo, 100mg, or 200mg of udenafil for 12 weeks, were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Question (GAQ) during the study period. Main Outcome Measures. The primary efficacy parameter was the change in the erectile function domain (EFD) score of IIEF from baseline. Secondary parameters were IIEF questions 3 (Q3) and Q4, SEP Q2 and Q3, rate of achieving normal erectile function (EFD≥26), and the response to GAQ. Results. Compared with the placebo, patients receiving both doses of udenafil showed statistically significant improvements in the IIEF-EFD score, respectively. However, statistically significant difference was not observed between the udenafil 100mg and the udenafil 200mg groups. Similar results were observed in the comparison of Q3 and Q4 of IIEF, SEP diary, and GAQ. The percentages of subjects experiencing at least one adverse event related to the study drugs were 3.6%, 15.8%, and 22.4% for the placebo, udenafil 100mg, and udenafil 200mg groups, respectively. However, these events were all mild in severity. Major adverse events were flushing, headache, nausea, and conjunctival hyperemia. Conclusion. Udenafil was significantly effective for the treatment of ED, demonstrating statistically significant improvement in erectile function in patients with DM. The incidence of adverse events was relatively low and well tolerated in patients with DM.
AB - Introduction. Patients with diabetes mellitus (DM) are reported to experience more severe erectile dysfunction (ED) symptoms and respond less to ED treatments compared with patients with ED of other etiologies. Aim. This study was undertaken to evaluate the safety and efficacy of udenafil for the treatment of ED in a larger number of patients with DM. Methods. A placebo-controlled, randomized, double-blind, double-dummy, parallel-group design multicenter study, fixed-dose trial was conducted. The trial involved seven study sites in Korea, with 174 ED patients with DM. The subjects, treated with placebo, 100mg, or 200mg of udenafil for 12 weeks, were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Question (GAQ) during the study period. Main Outcome Measures. The primary efficacy parameter was the change in the erectile function domain (EFD) score of IIEF from baseline. Secondary parameters were IIEF questions 3 (Q3) and Q4, SEP Q2 and Q3, rate of achieving normal erectile function (EFD≥26), and the response to GAQ. Results. Compared with the placebo, patients receiving both doses of udenafil showed statistically significant improvements in the IIEF-EFD score, respectively. However, statistically significant difference was not observed between the udenafil 100mg and the udenafil 200mg groups. Similar results were observed in the comparison of Q3 and Q4 of IIEF, SEP diary, and GAQ. The percentages of subjects experiencing at least one adverse event related to the study drugs were 3.6%, 15.8%, and 22.4% for the placebo, udenafil 100mg, and udenafil 200mg groups, respectively. However, these events were all mild in severity. Major adverse events were flushing, headache, nausea, and conjunctival hyperemia. Conclusion. Udenafil was significantly effective for the treatment of ED, demonstrating statistically significant improvement in erectile function in patients with DM. The incidence of adverse events was relatively low and well tolerated in patients with DM.
KW - Diabetes mellitus
KW - Erectile dysfunction
KW - Pharmacotherapy for erectile dysfunction in men with diabetes
KW - Udenafil
UR - http://www.scopus.com/inward/record.url?scp=79960467698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960467698&partnerID=8YFLogxK
U2 - 10.1111/j.1743-6109.2011.02268.x
DO - 10.1111/j.1743-6109.2011.02268.x
M3 - Article
C2 - 21554549
AN - SCOPUS:79960467698
VL - 8
SP - 2048
EP - 2061
JO - Journal of Sexual Medicine
JF - Journal of Sexual Medicine
SN - 1743-6095
IS - 7
ER -